Alinamin

Alinamin is a Japanese pharmaceutical and health-care brand centered on vitamin B1 preparations. The brand originated in the postwar Japanese pharmaceutical market and became associated with fursultiamine, a vitamin B1 derivative designed to improve the practical absorption and utilization of thiamine compared with conventional vitamin B1 preparations. Its early products were positioned for conditions and symptoms associated with vitamin B1 deficiency, including fatigue and certain nerve-related complaints, subject to the indication and formulation approved in each market. The brand was developed by Takeda Pharmaceutical Company and first marketed in Japan in 1954. Its name became widely recognized through oral vitamin B1 products and later through a broader range of preparations, including tablets, capsules, drinks and other formulations. Alinamin products have been marketed as medicines, quasi-drugs or health-care products depending on the product and jurisdiction; the regulatory classification and permitted claims therefore vary between Japan, Taiwan and other markets. Alinamin’s historical importance comes from the way it combined a pharmaceutical vitamin formulation with consumer-oriented branding. Rather than remaining only a hospital or prescription product, the brand was promoted for everyday concerns such as tiredness and lack of energy, helping make vitamin B1 supplementation a familiar category in Japan. The brand has also been linked with injectable formulations used in medical settings, although individual products and indications should not be generalized across the entire Alinamin portfolio. Corporate ownership changed as Takeda reorganized its consumer-health activities. Alinamin Pharmaceutical became the dedicated company associated with the brand, and Otsuka Holdings announced the acquisition of Alinamin Pharmaceutical from Takeda in 2020. The transaction placed Alinamin within the Otsuka Group while preserving the brand’s focus on vitamin B1-related medicines and consumer health. Today, Alinamin remains an active Japanese brand with products marketed primarily in Japan and with related presence in Taiwan and other markets. Exact product names, formulations, indications and availability differ by country, and the brand should not be treated as a single uniform medicine worldwide.

Alinamin emerged from Takeda Pharmaceutical’s work on vitamin B1 products in postwar Japan. Conventional thiamine preparations were useful but had limitations in absorption and practical delivery. Takeda researchers developed fursultiamine, a fat-soluble derivative of vitamin B1, and used the Alinamin name for products based on this technology. The first Alinamin product was introduced in Japan in 1954. The brand’s development reflected two important changes in Japanese health care. First, vitamin B1 was increasingly associated not only with deficiency disease but also with fatigue and nerve-related symptoms encountered in ordinary life. Second, pharmaceutical companies were learning to present medicines through memorable consumer brands. Alinamin combined these trends: it retained a pharmaceutical identity while becoming familiar to the general public through oral products and later drink-format products. Over time, Alinamin became an umbrella-style brand covering multiple formulations and regulatory categories. Depending on the product, the range has included oral medicines, liquid products, injectable preparations and other vitamin-focused health-care items. The common association has been vitamin B1 or a vitamin B1 derivative, especially fursultiamine. However, the formulation, dosage, indication and legal classification are not identical across the portfolio or across countries. The brand was originally part of Takeda’s pharmaceutical business. As Takeda reshaped its operations and separated or reorganized consumer-health activities, Alinamin Pharmaceutical became the corporate vehicle most directly associated with the brand. In August 2020, Otsuka Holdings announced an agreement to acquire Alinamin Pharmaceutical from Takeda. Completion of the transaction moved the brand into the Otsuka Group and made it part of Otsuka’s consumer-health and pharmaceutical interests. Alinamin has also had a presence outside Japan, including Taiwan, where local product registration, naming, distribution and permitted claims may differ from those in Japan. The brand’s current identity is therefore best understood as a Japanese-origin vitamin B1 pharmaceutical and consumer-health brand rather than as a single globally standardized product. Its continuing market role is based on the combination of established pharmaceutical heritage, vitamin B1 technology and everyday fatigue-care positioning.

1. 2020Otsuka announces acquisition of Alinamin Pharmaceutical

   Otsuka Holdings announced an agreement to acquire Alinamin Pharmaceutical from Takeda, bringing the company and its principal brand into the Otsuka Group.

   Source
2. 1954Alinamin introduced in Japan

   Takeda introduced the first Alinamin product in Japan, establishing the brand around vitamin B1-related pharmaceutical preparations.

   Source

A trusted Japanese vitamin B1 and fatigue-care brand combining pharmaceutical heritage with accessible consumer health products. Product claims and classifications depend on the specific formulation and market.

• Alinamin tabletsOral vitamin B1 medicine1954

  The tablet line represents the brand’s core oral pharmaceutical format. Products in this category are based on vitamin B1-related compounds, including formulations associated with fursultiamine. Depending on the specific product and jurisdiction, labeling may refer to vitamin B1 deficiency, fatigue, nerve-related symptoms or other approved indications. Strength, dosage and regulatory status differ by product.

• Alinamin drink productsLiquid consumer health product

  Alinamin drink products adapt the vitamin B1-centered brand to a convenient liquid format. They are associated with the Japanese market for fatigue-care and nutritional supplementation, but individual products may be classified as medicines, quasi-drugs or other health-care goods. Their ingredients, claims and recommended use should be checked against the label for the specific product.

• Alinamin injection productsInjectable vitamin B1 preparation

  Injectable Alinamin preparations have been associated with medical-use vitamin B1 therapy and with fursultiamine-based formulations. They are distinct from consumer drink and tablet products because administration, indications and supply are governed by local medical regulations. Availability and product details vary by market.

• 2020Transfer of Alinamin Pharmaceutical to OtsukaM&A

  Takeda was restructuring its portfolio while Otsuka was expanding its consumer-health activities. Alinamin Pharmaceutical was the company responsible for the Alinamin brand and related products.

  What changed. Otsuka Holdings announced an agreement to acquire all shares of Alinamin Pharmaceutical from Takeda Pharmaceutical.

  Aftermath. The brand moved from Takeda ownership into the Otsuka Group. The announcement did not indicate that the Alinamin name or product identity would be discontinued.

  Source

• 2020Otsuka Holdings to acquire Alinamin Pharmaceutical from Takeda

  Otsuka Holdings announced an agreement to acquire Alinamin Pharmaceutical, the company associated with the Alinamin brand, from Takeda Pharmaceutical. The transaction expanded Otsuka’s consumer-health portfolio and transferred the brand away from Takeda ownership.

  M&A
  Source

1. Alinamin official website
2. Otsuka Holdings announcement on the acquisition of Alinamin Pharmaceutical